(ACN Newswire) – The Lubrizol Corporation announces an alliance between Lubrizol LifeSciences, a leading supplier of advanced materials for the healthcare industry, and Particle Sciences, an integrated provider of drug development services. This alliance offers customers a comprehensive solution providing a range of materials, drug development and commercial manufacturing services that is one of the most comprehensive in the pharmaceutical industry.
Lubrizol’s recent acquisition of contract manufacturer Vesta, in combination with Lubrizol’s alliance with Particle Sciences, means that the LifeSciences business now offers complete solutions for sustained, controlled release and combination products from polymer supply and drug product development through quality manufacturing services. Lubrizol LifeSciences (booth 1817) will officially launch its alliance with Particle Sciences (booth 2911) at the American Association of Pharmaceutical Scientists (AAPS) conference Nov. 2-6 at the San Diego Convention Center.
“We’ve broadened our offering and further reinforced our commitment to the pharmaceutical market,” says Jean Claude Deneuville, Lubrizol LifeSciences director of the Pharma Solutions business. “By joining forces with Vesta and working with Particle Sciences, we have further expanded our set of skills and brought full-service solutions to the market.” Lubrizol LifeSciences now offers a combination of world class polymer technology, drug product development services, clinical supply, applications know-how and commercial manufacturing.
“Teaming up with both Vesta and Particle Sciences enables Lubrizol to leverage our core polymer chemistry into tailored solutions for novel implantable and dermal drug delivery systems and combination products to deliver improved patient outcomes,” says Joey Glassco, global market manager for Lubrizol LifeSciences.
Particle Sciences, based in Bethlehem, PA., is one of the world’s leading contract drug development and manufacturing organizations (CDMO) with a comprehensive suite of services including analytic, bio-analytic, physical characterization and manufacturing, all focused on the formulation and support of advanced drug delivery solutions. Its leadership in drug eluting product development and breadth of development technologies has earned it business with life sciences companies ranging from start-ups to more than half of the top 10 pharmaceutical and biotech leaders.
The recent acquisition of Vesta, a leading contract manufacturer to the medical device industry, broadens Lubrizol’s life science manufacturing capabilities, applications and material portfolio with access to silicone polymers and a variety of thermoplastics utilized in medical devices, advanced wound care and drug eluting products such as subcutaneous implants and intravaginal rings. Headquartered in Franklin, WI, Vesta leverages over four decades of engineering expertise and manufacturing experience to service clinical device applications with the quality that customers trust.
Source: The Lubrizol Corporation